Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 1, 2009, Pages 74-78

  Nomura, Kenichi ^a,b   Fujimoto, Yoshiko ^a   Yamashita, Mihoko ^a   Morimoto, Yasutaka ^a   Ohshiro, Muneo ^a   Sato, Kazumi ^c   Oyake, Tatsuo ^d   Kowata, Shugo ^d   Konishi, Hideyuki ^a   Yoshikawa, Toshikazu ^a   Ishida, Yoji ^d   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Kyoto Prefectural Institute of Public Health and Environment   (Japan)

^c National Hospital Organization Minami Kyoto Hospital   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Clostridium difficile; Endoscopic features; Immunosuppressive agents; Pseudomembrane

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CYCLOSPORIN A; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISOLONE; VANCOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLON ULCER; COLONOSCOPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MICROBIOLOGICAL EXAMINATION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; COLITIS, ULCERATIVE; COLONOSCOPY; DIARRHEA; DRUG THERAPY, COMBINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FECES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; METRONIDAZOLE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 58149084782     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802321238     Document Type: Article

References (18)

1. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
2. Pituch H, Rupnik M, Obuch-Woszczatynski P, Grubesic A, Meisel-Mikolajczyk F, Luczak M. Detection of binary-toxin genes (cdtA and cdtB) among Clostridium difficile strains isolated from patients with C. difficile-associated diarrhoea (CDAD) in Poland. J Med Microbiol 2005;54:143-7.
3. Nomura K, Fukumoto K, Shimizu D, Okuda T, Yoshida N, Kamitsuji Y, et al. Pseudomembranous colitis presenting as acute colonic obstruction without diarrhea in a patient with gastric Burkitt lymphoma. World J Gastroenterol 2005;11:2681-3.
4. Morimoto Y, Nomura K, Tsutsumi Y, Ohshiro M, Fujimoto Y, Shimizu D, et al. Clostridium difficile-associated diarrhea with hematochezia is associated with ulcer formation. Scand J Gastroenterol. In press.
5. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673-7.
6. LaMont JT. Bacterial infection of the colon. In: Yamada T, editor. Textbook of gastoroenterology. Philadelphia: Lippincott Williams & Wilkins; 2003. p 1954.
7. Mogg GA, Keighley MR, Burdon DW, Alexander-Williams J, Youngs D, Johnson M, et al. Antibiotic-associated colitis: A review of 66 cases. Br J Surg 1979;66:738-42.
8. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002;162:2177-84.
9. Boardman A. Diagnosis and management of pseudomembranous colitis and Clostridium difficile-associated disease. Primary Care Update for OB/GYNS, 1998;5:219-28.
10. Tsujimura H, Sakai C, Ishii A, Takagi T, Kumagai K. Fatal fulminant Clostridium difficile colitis during CHOP therapy for lymphoma: an autopsy case. Intern Med 2007;46:401-4.
11. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.
12. Wang A, Takeshima F, Ikeda M, Ohnita K, Furusu H, Isomoto H, et al. Ulcerative colitis complicating pseudomembranous colitis of the right colon. J Gastroenterol 2002;37:309-12.
13. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008;57:205-10.
14. Nomura K, Kamitsuji Y, Kono E, Matsumoto Y, Yoshida N, Konishi H, et al. Severe cytomegalovirus enterocolitis after standard chemotherapy for non-Hodgkin's lymphoma. Scand J Gastroenterol 2005;40:604-6.
15. Safdar N, Maki DG, The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834-44.
16. Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 2007;28:932-40.
17. Nomura K, Morikawa N, Ikawa K, Ikeda K, Fujimoto Y, Shimizu D, et al. Optimized dosage and method of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 2008;61:892-900.
18. Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004;33:1143-50.